Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : FPA Medical Management - FPAMQ -- Ignore unavailable to you. Want to Upgrade?

To: Douglas V. Fant who wrote (488)	5/11/1998 6:34:00 PM
From: Gary Leger	Read Replies (2) \| Respond to of 1110

DOUG, Thanks for the rationale on fpam. I hope you're right because I'm part of the suffering longs. If you are right these overbeaten stocks usually retrace about 50% of their loss, i.e.17 to 18. However, my concern is with the assumption there will be 20 or 30% growth with fpam during a time when they are curtailing their acquisitions and there seems to be a lot of concern over cutbacks in federal funding etc. The recent articles concerning the value the ppm industry adds to the equation brings some level of doubt to the business model itself, although it sure seems to make lots of sense to me in theory. Clearly most are enamored with the single specialty practice model. It also makes me wonder why the new ceo didn't move up the earnings release a day or two if there's any good news/guidance??

To: Douglas V. Fant who wrote (488)	5/13/1998 4:15:00 PM
From: Alfredo Nova	Read Replies (2) \| Respond to of 1110

To all: I recently became interested in FPAM because of its good reputation and declining stock value. It is a shame that First Boston downgraded the stock, joining the other brokerage houses. Their previous buy rating with a target of 40-45 in 12 mos had my buy some shares at 16.5. I read the company report and it seems that Dr Dresnick should be good for the job. In addition, I don't think Humana would give them 23 center to run if they had no confidence in the new management. We will probably expect a more prudent course, reduction in debt (always a good thing) and hopefully a decent growth. The current low price/sales ratio, even compared to Phycor, should provide decent support for the stock. Just some thought, I don't function too well since I had a tonsillectomy last week and I surely don't wish this to anybody, regards Alfredo